---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014831"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:55:01.791140+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform

## Summary
- Joint development, manufacturing, and licensing agreement signed March 31, 2026.
- Combines Oncotelic's proprietary PDAOAI platform with TechForce's robotics hardware.
- Platform targets GMP-compliant automated material handling, monitoring, and compliance workflows.
- Financial terms not disclosed; revenue sharing and royalties to be negotiated in future agreement.
- AI foreground IP owned by Oncotelic; jointly developed IP jointly owned.

## SEC filing metadata
- accession: 0001493152-26-014831
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014831
- JSON: https://secwatch.observer/filing/0001493152-26-014831.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014831.txt

## Source-grounded claims
- claim_id: 43f800e0f106f153773fec249f3116f99846180f
  claim: Oncotelic Therapeutics, Inc. entered into Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. valued at Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice (effective 2026-03-31).
  evidence_excerpt: On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.